NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the 30th Annual Scientific Sessions of the Heart Rhythm Society, which run from May 13 to 16 in Boston. Highlights of the week's events include late-breaking trial presentations from the MADIT II clinical trial and the ALTITUDE Clinical Science Program. These presentations will provide new insights for implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) patients.
Schedule of Events (all times are Eastern Time)
Tuesday, May 12
- Cardiac Rhythm Management Allied Health Symposium. The Company will sponsor the "Tenth Annual Essentials of CRM Therapy and Patient Management," chaired by Mark Heimann, MSN, CS, CRNP, from 7:30 a.m. to 2:30 p.m. in the America Ballroom at the Westin Copley Place Hotel, 10 Huntington Ave., Boston. This symposium is designed to provide clinicians with practical knowledge on the care and management of patients who have an implantable CRM device or are undergoing an electrophysiology procedure.
Wednesday, May 13
- Insights into Percent Biventricular Pacing in Heart Failure Patients. David L. Hayes, M.D., will present on the impact of biventricular pacing on CRT-D patients from the ALTITUDE Clinical Science Program. This observational cohort study analyzes data from more than 100,000 remote monitoring patients and looks at the relative risk of mortality among patients grouped by the percent biventricular pacing therapy they receive. The results will be presented during a poster session from 5:45 to 7:00 p.m. in the Grand Ballroom at the Westin Waterfront Hotel, 425 Summer St., Boston.
- Cardiac Rhythm Management Symposium. The Company will sponsor the 21st Annual Michel Mirowski Sudden Cardiac Arrest Symposium and Award Presentation from 7:00 to 9:00 p.m. in the America Ballroom at the Westin Copley Place Hotel. The event will begin with opening remarks by N. A. Mark Estes III, M.D., followed by the award ceremony honoring this year's Mirowski Award recipient, Michel Haissaguerre, M.D. Michael Gold, M.D., Ph.D., will then lead a panel discussion, including Arthur Moss, M.D., Michael Ackerman, M.D., and Frederic Sacher, M.D., regarding the latest data on the predictors of sudden cardiac death.
Thursday, May 14
- Survival after ICD and CRT-D Implant. Leslie Saxon, M.D., will present data on survival rates from the ALTITUDE Clinical Program. The results will be presented at 10:30 a.m. during a late-breaking trial session in the West Ballroom of the Boston Convention and Exhibition Center. The Company plans to issue a press release at this time.
- Extended Survival Analysis from MADIT II. Ilan Goldenberg, M.D., will present an analysis from the MADIT II trial of the cumulative probability of all-cause mortality for primary prevention patients at eight years post-implant. The results will be presented at 10:45 a.m. during a late-breaking trial session in the West Ballroom of the Boston Convention and Exhibition Center. The Company plans to issue a press release at this time.
- Risk Factors for All-cause Mortality with CRT. John P. Boehmer, M.D., Brian Jaski, M.D., and Steven Higgins, M.D., will present risk stratification data for mortality among various sub-groups of heart failure patients receiving CRT therapy. The results will be presented during an oral presentation from 2:15 to 2:30 p.m. in Room 255 of the Boston Convention and Exhibition Center.
Friday, May 15
- The Effects of Atrial Support Pacing in CRT Patients. Preliminary data from the PEGASUS-CRT Trial will be presented by David O. Martin, M.D. PEGASUS-CRT is the first large-scale study evaluating the effects of atrial support pacing on clinical outcomes in heart failure patients receiving CRT-D devices. The results will be presented at 8:00 a.m. during a late-breaking trial session in the East Ballroom of the Boston Convention and Exhibition Center.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth strategies. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: David Knutson
Boston Scientific Corporation
Boston Scientific Corporation
Boston Scientific Corporation
Heart Rhythm Society
Related biology technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved
. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University2
. UMass Boston Opens Venture Development Center to Expand R&D Activity3
. Boston Scientific Announces First Quarter Special Items4
. Boston Scientific Launches New Coronary Imaging Catheter5
. Moodys Raises Boston Scientifics Rating Outlook to Stable6
. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University7
. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston8
. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory9
. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge10
. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System11
. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor